Methotrexate drug interactions in the treatment of rheumatoid arthritis: A systematic review

Journal of Rheumatology

Volumn 37, Issue 7, 2010, Pages 1416-1421

  Bourré Tessier, Josiane ^a   Haraoui, Boulos ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Drug interactions; Methotrexate; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; FOLINIC ACID; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL TRIAL; CYTOPENIA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG INTERACTIONS; HEMATOLOGIC DISEASES; HUMANS; METHOTREXATE; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 77954429186     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090153     Document Type: Article

References (68)

1. Fries J, Singh G, Lenert L, Furst D. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990;33:1611-9.
2. Rooney T, Furst D, Koehnke R, Burmeister L. Aspirin is not associated with more toxicity than other nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1993;20:1297-302. (Pubitemid 23310978)
3. Mor A, Ahn S, Izmirly P, Reddy S, Greenberg J, Bingham C, et al. Methotrexate combined with INH anti-tuberculous prophylaxis is well tolerated in RA patients. Ann Rheum Dis 2008;67:462-5.
4. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-2.
5. Al-Awadhi A, Dale P, McKendry R. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993;20:1121-5. (Pubitemid 23278160)
6. Kaneko Y, Suwa A, Ikeda Y, Hirakata M. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Mod Rheumatol 2006;16:36-8.
7. Sosin M, Handa S. Low dose methotrexate and bone marrow suppression. BMJ 2003;326:266-7.
8. Saravana S, Lalukotta K. Myelotoxicity due to methotrexate - an iatrogenic cause [letter]. Eur J Haematol 2003;71:315-6.
9. Chevrel G, Brantus JF, Sainte-Laudy J, Miossec P. Allergic pancytopenia to trimethoprim-sulphamethoxazole for pneumocystis carinii pneumonia following methotrexate treatment for rheumatoid arthritis [letter]. Rheumatology 1999;38:475-6.
10. Steuer A, Gumpel JM. Methotrexate and trimethoprim: a fatal interaction [letter]. Br J Rheumatol 1998;37:105-6. (Pubitemid 28371831)
11. Nygaard H. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis [letter]: comment on the article by Gutierrez-Urena, et al. Arthritis Rheum 1997;40:194-5.
12. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996;15:266-70.
13. Govert J, Patton S, Fine R. Pancytopenia from using trimethoprim and methotrexate [letter]. Ann Intern Med 1992;117:877-8.
14. Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole - a potentially hazardous combination. Clin Exp Dermatol 1990;15:358-60.
15. Jeurissen M, Boerbooms A, van de Putte L. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole [letter]. Ann Intern Med 1989;111:261.
16. Buchbinder R, Hall S, Ryan PFJ, Littlejohn GO, Harkness JG. Severe bone marrow failure due to low dose oral methotrexate [letter]. J Rheumatol 1988;15:1586-8.
17. Thevenet JP, Ristori JM, Cure H, Mizony MH, Bussiere JL. Pancytopenia during treatment of rheumatoid arthritis with methotrexate after administration of trimethoprim-sulfamethoxazole. Presse Med 1987;16:1487.
18. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986;13:440-1.
19. Maricic M, Davis M, Gall E. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 1986;29:133-5.
20. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen [letter]. Lancet 1986;i:1390.
21. Kraus A, Alarcon-Segovia D. Low dose MTX and NSAID induced "mild" renal insufficiency and severe neutropenia [letter]. J Rheumatol 1991;18:1274.
22. Ohosone Y, Okano Y, Kameda H, Hama N, Mimori T, Akizuki M, et al. Clinical characteristics related to methotrexate-induced pancytopenia [letter]. Clin Rheumatol 1997;16:321-3.
23. Calvo-Romero JM. Severe pancytopenia associated with low-dose methotrexate therapy for rheumatoid arthritis. Ann Pharmacother 2001;35:1575-7.
24. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18:609-10.
25. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992;26:234-7.
26. Thonofer R, Kriessmayr M, Thonofer U, Wipfler E, Uitz E, Bahadori B, et al. Rheumatoid arthritis patients with therapy-induced myelodysplastic syndrome present with long-term remission after recovery. Scand J Rheumatol 2007;36:149-50.
27. Berthelot JM, Maugars Y, Hamidou M, Chiffoleau A, Barrier J, Grolleau J, et al. Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths). Rev Rhum (Engl Ed) 1995;62:477-86.
28. Tanaka Y, Shiozawa K, Nishibayashi Y, Imura S. Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy? [letter]. J Rheumatol 1992;19:1320-1.
29. Laroche F, Perrot S, Menkes CJ. Pancytopenia in rheumatoid arthritis patients receiving methotrexate. Presse Med 1996;25:1144-6.
30. Serraj K, Federici L, Maloisel F, Alt M, Andres E. Pancytopenia related to low-dose methotrexate: study of five cases and review of the literature. Rev Med Interne 2007;28:584-8.
31. Maier WP, Leon-Perez R, Miller SB. Pneumonitis during low-dose methotrexate therapy. Arch Intern Med 1986;146:602-3.
32. Doolittle GC, Simpson KM, Lindsley HB. Methotrexate-associated, early-onset pancytopenia in rheumatoid arthritis. Arch Intern Med 1989;149:1430-1.
33. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. Med J Aust 1991;155:480-4.
34. Herrick AL, Grennan DM, Aarons L. Lack of interaction between methotrexate and penicillins [letter]. Rheumatology 1999;38:284-5. (Pubitemid 29507168)
35. Nanke Y, Kotake S, Akama H, Tomii M, Kamatani N. Pancytopenia and colitis with clostridium difficile in a rheumatoid arthritis patient taking methotrexate, antibiotics and non-steroidal anti-inflammatory drugs. Clin Rheumatol 2001;20:73-5. (Pubitemid 32208454)
36. Blackburn W Jr, Alarcon G. Toxic response to topical fluorouracil in two rheumatoid arthritis patients receiving low-dose, weekly methotrexate. Arthritis Rheum 1990;33:303-4. (Pubitemid 20098680)
37. Gutierrez-Urena S, Molina J, Garcia C, Cuellar M, Espinoza L. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:272-6.
38. Marshall RW, Marshall VJ, Hull R. Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event [letter]. Rheumatology 2006;45:362-3.
39. Sichere P, Maudhuit F, Hatem-Schliacowsky N. Pancytopenia during the treatment of rheumatoid polyarthritis by low doses of methotrexate. A new case that can question its combination with ranitidine. Rev Rhum 1990;57:593.
40. Richmond R, Microrie E, Ogden D, Lambert M. Methotrexate and triamterene - a potentially fatal combination? [letter]. Ann Rheum Dis 1997;56:209-10.
41. Dubost J, Sauvezie B. Fatal bone marrow toxicity in a patient treated with methotrexate and glafenine for rheumatoid arthritis [letter]. Clin Exp Rheumatol 1988;6:97-9.
42. Vincent S, Slease R, Rocca P. Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics? Delaware Med J 2002;74:469-73.
43. Omdal R, Goransson L, Bergrem H. Fatal outcome of low-dose methotrexate therapy in rheumatoid arthritis [letter]. Clin Rheumatol 1993;12:283-4. (Pubitemid 23246772)
44. Alexandre C, Chaffanjon C, Tavan P, Thomas T, Pallot-Prades B, Prallet B, et al. Bone marrow aplasia in rheumatoid polyarthritis treated with low-dose methotrexate [letter]. Rev Rhum 1990;57:233-4.
45. MacKinnon S, Starkebaum G, Wilkens R. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985;15:119-26.
46. McArthur G, Cole-sinclair M, Van der Weyden M. Haemopoietic toxicity and low-dose methotrexate [letter]. Med J Aus 1992;156:296.
47. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
48. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990;47:540-6.
49. Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 1990;17:1008-10.
50. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991;34:1514-20.
51. Seideman P, Muller-Suur R. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 1993;52:613-5. (Pubitemid 23246668)
52. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994;37:453-6. (Pubitemid 24197139)
53. Furst DE, Herman RA, Koehnke R, Ericksen N, Hash L, Riggs CE, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-6.
54. Kremer J, Hamilton R. The effects of nonsteroidal anti-inflammatory drugs on methotrexate pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22:2072-7.
55. Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005;45:1179-86.
56. Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, Chales GH, Juvin RR, et al. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann Pharmacother 2004;38:1582-7.
57. Hamilton SF, Campbell NR, Kara M, Watson J, Connors M. The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis. J Rheumatol 2003;30:1948-50.
58. Schwartz JI, Agrawal NG, Wong PH, Bachmann KA, Porras AG, Miller JL, et al. Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. J Clin Pharmacol 2001;41:1120-30.
59. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific cox-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999;26:2539-43.
60. Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Hussain MA. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 1998;19:163-7.
61. Hubner G, Sander O, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997;24:845-51.
62. Herrick AL, Grennan DM, Griffen K, Aarons L, Gifford LA. Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. Br J Clin Pharmacol 1996;41:223-7. (Pubitemid 26078296)
63. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis. J Rheumatol 1996;23:984-9. (Pubitemid 26196085)
64. Combe B, Edno L, Lafforgue P, Bologne C, Bernard JC, Acquaviva P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995;34:421-8.
65. Anaya JM, Fabre D, Bressolle F, Bologna C, Alric R, Cocciglio M, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1994;21:203-8.
66. Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988;15:1356-60.
67. Svendsen KB, Bech JN, Pfeiffer-Jensen M, Stengaard-Pederson K, Pederson EB. Urinary excretion of alpha-GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs. Scand J Rheumatol 2005;34:34-9.
68. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2008;68:1086-93; E-pub Nov 25.